09:28 AM EST, 11/10/2025 (MT Newswires) -- MannKind ( MNKD ) said Monday it has discontinued its phase 3 trial evaluating MNKD-101, a nebulized clofazimine inhalation suspension, for the treatment of nontuberculous mycobacterial lung disease.

The company said no sputum culture conversions were observed from the first 46 participants who completed the double-blind treatment phase and the Data Safety Monitoring Board agreed with the decision to discontinue the trial due to futility.

MannKind ( MNKD ) said the the outcome does not affect plans for MNKD-102, its dry powder inhalation clofazimine, which remains under consideration for future clinical development.

MannKind ( MNKD ) shares were down 7.5% in recent Monday premarket activity.